Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Re: High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphatic leukemia.

× No keyword cloud information.

10 in total

1. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.

Authors: D H Mahoney; J J Shuster; R Nitschke; S J Lauer; C P Steuber; N Winick; B Camitta
Journal: J Clin Oncol Date: 1998-05 Impact factor: 44.544

2. Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Münster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study--a report from the Associazione Italiana Ematologia Oncologia Pediatrica.

Authors: C Rizzari; M G Valsecchi; M Aricò; V Conter; A Testi; E Barisone; F Casale; L Lo Nigro; R Rondelli; G Basso; N Santoro; G Masera
Journal: J Clin Oncol Date: 2001-03-01 Impact factor: 44.544

3. High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia.

Authors: T V Ch Skärby; H Anderson; J Heldrup; J A Kanerva; H Seidel; K Schmiegelow
Journal: Leukemia Date: 2006-09-21 Impact factor: 11.528

4. Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate.

Authors: Brenda J Spiegler; Kimberly Kennedy; Ronnen Maze; Mark L Greenberg; Sheila Weitzman; Johann K Hitzler; Paul C Nathan
Journal: J Clin Oncol Date: 2006-08-20 Impact factor: 44.544

5. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study.

Authors: J Pullen; J Boyett; J Shuster; W Crist; V Land; L Frankel; R Iyer; L Backstrom; J van Eys; M Harris
Journal: J Clin Oncol Date: 1993-05 Impact factor: 44.544

6. Cerebrospinal fluid drug levels of leukemic children receiving intravenous 5 g/m2 methotrexate.

Authors: F Millot; H Rubie; F Mazingue; F Mechinaud; A Thyss
Journal: Leuk Lymphoma Date: 1994-06

Review 7. Defining the appropriate dosage of folinic acid after high-dose methotrexate for childhood acute lymphatic leukemia that will prevent neurotoxicity without rescuing malignant cells in the central nervous system.

Authors: Ian J Cohen
Journal: J Pediatr Hematol Oncol Date: 2004-03 Impact factor: 1.289

8. High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia.

Authors: Arend von Stackelberg; Reinhard Hartmann; Christoph Bührer; Rüdiger Fengler; Gritta Janka-Schaub; Alfred Reiter; Georg Mann; Kjeld Schmiegelow; Richard Ratei; Thomas Klingebiel; Jörg Ritter; Günter Henze
Journal: Blood Date: 2007-12-18 Impact factor: 22.113

9. How much is too much? Folinic acid rescue dose in children with acute lymphoblastic leukaemia.

Authors: J D Borsi; F Wesenberg; T Stokland; P J Moe
Journal: Eur J Cancer Date: 1991 Impact factor: 9.162

10. In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile.

Authors: Michael J Sorich; Nicolas Pottier; Deqing Pei; Wenjian Yang; Leo Kager; Gabriele Stocco; Cheng Cheng; John C Panetta; Ching-Hon Pui; Mary V Relling; Meyling H Cheok; William E Evans
Journal: PLoS Med Date: 2008-04-15 Impact factor: 11.069

10 in total